Stay updated on Tucidinostat & Tislelizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Tucidinostat & Tislelizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucidinostat & Tislelizumab in NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The ClinicalTrials.gov site footer now displays revision v3.8.0 instead of v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-31T15:38:41.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and provides links to updates and FAQs.
    Difference
    0.8%
    Check dated 2026-10-24T16:50:46.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site footer now identifies the software revision as v3.7.2 instead of v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-17T16:37:30.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-10T16:36:17.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    A new revision entry v3.7.0 was added to the study record history and the previous v3.6.6 entry was removed, indicating an update to the platform version shown in the history list.
    Difference
    0.1%
    Check dated 2026-09-19T22:17:19.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The record history now includes Revision: v3.6.6, indicating a new version of the study record has been released, replacing the previous v3.6.5 revision.
    Difference
    0.1%
    Check dated 2026-08-29T19:15:36.000Z thumbnail image

Stay in the know with updates to Tucidinostat & Tislelizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucidinostat & Tislelizumab in NSCLC Clinical Trial page.